Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Premaitha's Revenues Double in FY 2017 Following Acquisition

Premaitha's Revenues Double in FY 2017 Following Acquisition

May 15, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Premaitha Health today reported a doubling of revenues for its fiscal year 2017, which ended March 31, and said that it has raised £2.5 million ($3.37 million) in new funding through a share subscription. The firm also provided an update on its business and on its patent litigation with Illumina.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  2. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  3. Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

    Premium

  4. ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

  5. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.